Ivantis, Inc. Completes $475 Million Sale to Alcon

Represented Ivantis, Inc. in its $475 million sale to Geneva-based Alcon (SWC: ALC). Ivantis is a developer of a surgical device designed for the treatment of glaucoma and other eye diseases. The company’s Hydrus Microstent is a minimally invasive, intracanalicular scaffold that reduces eye pressure by re-establishing the patient's natural outflow pathway, providing the treatment of primary open angle glaucoma.